Contribute Try STAT+ Today

As Canadians brace for new rules to address prescription drug spending, a government report found sales of patented medicines rose a “modest” 3.5% in 2019 and that prices were stable, but a growing number of increasingly expensive, specialized treatments are driving overall costs higher.

Such medicines — such as biologics and cancer therapies — now account for approximately half of all sales of patented medicines in the country, a “dramatic” increase from 10% less than a decade ago, the report found. In 2009, only one of the top 10 selling patented medicines cost more than $1,000 a year. By 2019, seven of the top 10 had annual treatment costs exceeding $10,000 annually.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.